Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120

Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120

US Patent 11472868 · Granted Oct 18, 2022

Estimated economic value: $6,617,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Anti-HIV vaccine antibodies with reduced polyreactivity2025
Anti-HIV vaccine antibodies with reduced polyreactivity2025
Multivalent carriers and related vaccine compositions2025
Anti-HIV antibody 10-1074 variants2025
Human immunodeficiency virus neutralizing antibodies and methods of use thereof2025
Human immunodeficiency virus neutralizing antibodies and methods of use thereof2025
Human immunodeficiency virus neutralizing antibodies and methods of use thereof2025
Human immunodeficiency virus neutralizing antibodies and methods of use thereof2025
Broadly neutralizing antibodies that target HIV ENV V3 N-glycans2025
Broadly neutralizing antibodies that target HIV ENV V3 N-glycans2025
HIV vaccine immunogens2025
HIV vaccine immunogens2025